Welcome back to the journal review. This is Dermatologic Surgery, September twenty twenty-six, and this episode we're focusing on a single piece — an invited commentary, a letter to the editor style piece, responding to a recent NCDB analysis on penile squamous cell carcinoma surgical margins. Let's get into it.

This is a comment article — not original research itself, but a critical response written by a trio of European urologic oncologists, May, Lebentrau, and Albersen, reacting to a paper by Cheraghlou and colleagues that pulled over sixteen thousand cases of penile squamous cell carcinoma from the National Cancer Database across a sixteen-year window. Since this is a commentary rather than a primary study, there's no methods section of its own to walk through — instead, the value here is in how these authors interpret and contextualize someone else's data, and where they push back.

The underlying study these authors are responding to found some genuinely striking numbers. More than eighty-eight percent of participating institutions treated five or fewer penile squamous cell carcinoma patients per year — so this is an extremely fragmented, low-volume disease in the American surgical landscape, scattered across centers that each see it only rarely. And despite that, over two-thirds of patients — about sixty-eight and a half percent — underwent partial or total penectomy, even though only around eighteen percent of tumors were actually pT3 or pT4, and another quarter were pT2. In plain terms: the majority of patients got the most radical, most mutilating surgery, but the majority of tumors didn't have the stage to justify it. The commentary authors call this out sharply — this isn't just an unfortunate statistic, it's a mismatch between oncologic need and surgical radicality, playing out at scale.

The original paper's other headline finding, which the commentators highlight as particularly noteworthy, is that organ-preserving surgery was associated with better overall survival than partial penectomy, even after adjusting for both margin status and pathologic stage in a multivariable model. The effect size was modest in absolute terms — an odds ratio under one, right around point nine, and it was statistically significant — but the clinical message the commentators draw out is the important part: when you can achieve negative margins with organ-sparing technique, you're not trading survival for function. You may actually be getting both.

Now, where this commentary earns its place as more than just a summary is in its critique. The original study reported positive margin rates after organ-preserving surgery ranging from about eighteen percent in penile intraepithelial neoplasia up to thirty-seven and a half percent in pT3 disease — genuinely high numbers that would make any surgeon uncomfortable. But the commentators point out a real limitation: the NCDB data aren't stratified by the specific organ-preserving technique used. Wide local excision, glans resurfacing, glansectomy, laser ablation — these get lumped together, and they have very different oncologic performance profiles. Without that granularity, a headline positive-margin rate can be misleading, because it's averaging across procedures that aren't interchangeable.

Where the commentary really diverges from the original authors is on the proposed solution. Cheraghlou and colleagues suggested Mohs micrographic surgery might be a reasonable strategy to improve margin control in this disease. The European urologists are respectful but unconvinced — they note Mohs has essentially no foothold in urologic oncology pathways in Europe, and instead point to the European Association of Urology guidelines, which already support a risk-adapted, anatomically tailored framework: minimal macroscopic margins for low-risk tumors, since most penile tumors extend less than five millimeters beyond the visible lesion, and multiple studies show that microscopic margins over just one millimeter aren't linked to higher recurrence. Their argument, essentially, is that the tools for margin-conscious organ preservation already exist in urology — the real problem isn't technique, it's the system delivering it. Their proposed fix is centralization of care, minimum case-volume thresholds, integrated uropathology collaboration, and firmer guideline adherence, pointing to Northern European models where centralization has already improved outcomes.

Practically, for the Mohs surgeon and dermatologic oncologist listening to this, here's the useful frame. This isn't a paper telling you to start doing Mohs on penile shaft or glans lesions tomorrow — the commentators are explicit that this hasn't been adopted into urologic pathways and they don't think it should be the primary fix. What is worth carrying forward is the broader lesson about margin philosophy in a rare, anatomically constrained cancer: high positive-margin rates in a national database often reflect fragmented, low-volume care rather than an inherent limitation of organ preservation itself, and the data increasingly support that in low-risk disease, a positive or close margin doesn't necessarily translate into worse cancer-specific survival if you have structured follow-up and timely salvage. If you're ever consulted on a penile lesion, or find yourself in a multidisciplinary conversation about margin strategy in a site where radical extirpation carries real functional cost, this commentary is a good reminder that Mohs-style margin control has real conceptual appeal, but the burden of proof and infrastructure for extending it into urologic oncology simply isn't there yet. Interesting cross-disciplinary parallel, not yet actionable.

That's it for this episode. Thanks for listening, and I'll see you next time for the next installment of Dermatologic Surgery.